Navigation Links
PharmAthene Reports Second Quarter 2009 Financial and Operational Results
Date:8/13/2009

ANNAPOLIS, Md., Aug. 13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the second quarter and six months ended June 30, 2009.

For the second quarter of 2009, PharmAthene recognized revenues of $8.1 million compared to $11.7 million in the same period of 2008. For the six months ended June 30, 2009 and 2008, the Company reported revenues of $13.6 million and $17.5 million, respectively. Revenues for the three and six month periods ended June 30, 2009 consisted primarily of contract funding from the U.S. government for the development of Protexia((R)), SparVax(TM) and Valortim((R)).

Research and development expenses were $9.5 million and $12.3 million for the quarter ended June 30, 2009 and 2008, respectively. For the six months ended June 30, 2009 and 2008, research and development expenses were $15.2 million and $18.2 million, respectively. Expenses for each period consisted primarily of research and development activities related to programs for Valortim((R)) and Protexia((R)), and for the three month period ended June 30, 2009 also reflect activities related to the SparVax(TM), RypVax(TM) and the Company's third generation rPA anthrax vaccine programs.

General and administrative expenses for the Company were $4.4 million and $4.6 million for the quarter ended June 30, 2009 and 2008, respectively. For the six months ended June 30, 2009 and 2008, general and administrative expenses were $9.6 million and $9.0 million, respectively. General and administrative expenses were essentially flat for the three months ended June 30, 2009 and increased by approximately $600,000 in the first six months of
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
2. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
3. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
4. PharmAthene Reports First Quarter 2009 Financial and Operational Results
5. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
6. PharmAthene to Host First Quarter 2009 Conference Call and Webcast on Thursday, May 14, 2009
7. PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
8. PharmAthene Announces $5.5 Million Public Equity Offering
9. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
10. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
11. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it ... Wednesday, July 28, 2010 . , ... United Therapeutics will host a half-hour teleconference on Wednesday, ... teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A ...
... of the Chemical Engineering and Materials Science department ... Biology and Biomedical Engineering at Stevens Institute of ... their research entitled, "Evaporative Assembly of Drug-Eluting Bioresorbable ... of the pioneering work being undertaken by Professors ...
... - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" TSX: ... Meeting of Shareholders held today, its shareholders, including those shareholders ... voted to approve the merger of Datong Investment Inc. with ... and Plan of Merger dated March 26, 2010 , ...
Cached Biology Technology:NSF funds infection-resistant orthopedic research 2Dragon Pharma shareholders approve merger and seek termination of listing on the OTCBB and TSX 2
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... NVIDIA CUDA Teaching Centre in Canada. The ... electrical and computer engineering students how to tap ... units (GPU) and use them in computationally demanding ... that enables dramatic increases in computing performance for ...
... successful initial testing of a new form of methotrexate ... nose drops rather than injected. It shows promise as a ... appears in ACS, Molecular Pharmaceutics , a bi-monthly journal. ... is difficult to treat, partly because current anticancer drugs have ...
... major risk factor for disease, much of the threat ... a cluster of risk factors related to diabetes and ... many of these risk factors. However, many people struggle ... the University of Missouri have found that people who ...
Cached Biology News:McMaster, NVIDIA establish first CUDA Teaching Centre in Canada 2Putting on the pounds after weight loss? Hit the gym to maintain health gains 2
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... Shimadzus preparative LC/MS, using mass numbers as ... it ideal for performing investigation and research ... for both analytical and preparative operation. Switching ... in the software. This support provides a ...
... Label IT siRNA Tracker Intracellular Localization Kit ... label and deliver siRNA, of your design, ... in vitro tracking experiments. Subcellular localization and ... be monitored following introduction of the labeled ...
Selective media for Salmonella...
Biology Products: